Download PDF
Semin Thromb Hemost 2020; 46(05): 592-605
DOI: 10.1055/s-0039-3399568
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Applications of Nanotechnology in the Diagnosis and Therapy of Stroke

Lila M. Landowski
1   Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
,
Be'eri Niego
2   NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
,
Brad A. Sutherland
1   Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
,
Christoph E. Hagemeyer
2   NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
,
David W. Howells
1   Stroke Research Unit, School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2019 (online)

    Permissions and Reprints

Abstract

Stroke is a leading cause of death and disability worldwide. The classification of stroke subtypes is difficult but critical for the prediction of clinical course and patient management, and limited treatment options are available. There is an urgent need for improvements in both diagnosis and therapy. Strokes have rapidly evolving phases of damage involving unique compartments of the brain, which imposes severe limitations for current diagnostic and treatment procedures. The rapid development of nanotechnology in other areas of modern medicine has ignited a widespread interest in its potential for the field of stroke. An important feature of nanoparticles is the relative ease in which their structures and surface chemistries can be modified for specific and potentially multiple, simultaneous purposes. Nanoparticles can be synthesized to carry and deliver therapeutics to specific cellular or subcellular compartments; they can be engineered to provide enhanced contrast for imaging based on the detection of changes in the blood flow; or possess ligand-specific chemistries which can facilitate diagnosis and monitor the treatment response. More specifically for a stroke, nanoparticles can be engineered to release their payload in response to the distinct extracellular processes occurring around the clot and in the ischemic penumbra, as well as aid in the detection of pathological hallmarks present at various stages of stroke progression. These capacities allow targeted release of disease-modifying agents in the affected brain tissue, increasing treatment efficacy, and limiting unwanted side effects. While nanospheres, liposomes, and mesoporous nanostructures all emerge as future prospects for stroke treatment and diagnosis, much of this potential is yet to be clinically realized. This review outlines aspects of nanotechnology identified as having potential to revolutionize the field of stroke.

Keywords

nanotechnology - nanoparticles - therapeutic - stroke - diagnosis - theranostic - biomarkers - drug delivery - blood–brain barrier
 

  • References

  • 1 Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371 (9624): 1612-1623
    CrossrefPubMedGoogle Scholar
  • 2 Hackett ML, Köhler S, O'Brien JT, Mead GE. Neuropsychiatric outcomes of stroke. Lancet Neurol 2014; 13 (05) 525-534
    PubMedGoogle Scholar
  • 3 Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367 (9524): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 4 Muir KW, Buchan A, von Kummer R, Rother J, Baron J-C. Imaging of acute stroke. Lancet Neurol 2006; 5 (09) 755-768
    CrossrefPubMedGoogle Scholar
  • 5 Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32 (02) 200-219
    CrossrefPubMedGoogle Scholar
  • 6 Bracard S, Schmitt E. Vasospasm and delayed consequences. Interv Neuroradiol 2008; 14 (Suppl. 01) 17-22
    CrossrefPubMedGoogle Scholar
  • 7 Condette-Auliac S, Bracard S, Anxionnat R. , et al. Vasospasm after subarachnoid hemorrhage: interest in diffusion-weighted MR imaging. Stroke 2001; 32 (08) 1818-1824
    CrossrefPubMedGoogle Scholar
  • 8 Hacke W, Kaste M, Bluhmki E. , et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
    CrossrefPubMedGoogle Scholar
  • 9 Jauch EC, Saver JL, Adams Jr HP. , et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44 (03) 870-947
    CrossrefPubMedGoogle Scholar
  • 10 Stroke Foundation. Clinical Guidelines for Stroke Management 2017. Melbourne, Australia: Stroke Foundation; 2017
    Google Scholar
  • 11 Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56 (08) 1015-1020
    CrossrefPubMedGoogle Scholar
  • 12 Fink JN, Kumar S, Horkan C. , et al. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke 2002; 33 (04) 988-993
    CrossrefPubMedGoogle Scholar
  • 13 Faiz KW, Sundseth A, Thommessen B, Rønning OM. Reasons for low thrombolysis rate in a Norwegian ischemic stroke population. Neurol Sci 2014; 35 (12) 1977-1982
    CrossrefPubMedGoogle Scholar
  • 14 Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 630S-669S
    CrossrefPubMedGoogle Scholar
  • 15 Minnerup J, Wersching H, Ringelstein EB. , et al. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time. Stroke 2011; 42 (10) 2838-2843
    CrossrefPubMedGoogle Scholar
  • 16 Krogias C, Bartig D, Kitzrow M, Weber R, Eyding J. Trends of hospitalized acute stroke care in Germany from clinical trials to bedside. Comparison of nation-wide administrative data 2008-2012. J Neurol Sci 2014; 345 (1-2): 202-208
    CrossrefPubMedGoogle Scholar
  • 17 Sokolov SV, Tschulik K, Batchelor-McAuley C, Jurkschat K, Compton RG. Reversible or not? Distinguishing agglomeration and aggregation at the nanoscale. Anal Chem 2015; 87 (19) 10033-10039
    CrossrefPubMedGoogle Scholar
  • 18 Ruff Z, Cloetens P, O'Neill T, Grey CP, Eiser E. Thermally reversible nanoparticle gels with tuneable porosity showing structural colour. Phys Chem Chem Phys 2017; 20 (01) 467-477
    PubMedGoogle Scholar
  • 19 Wang F, He C, Han M-Y, Wu JH, Xu GQ. Chemical controlled reversible gold nanoparticles dissolution and reconstruction at room-temperature. Chem Commun (Camb) 2012; 48 (49) 6136-6138
    CrossrefPubMedGoogle Scholar
  • 20 Klajn R, Bishop KJM, Grzybowski BA. Light-controlled self-assembly of reversible and irreversible nanoparticle suprastructures. Proc Natl Acad Sci U S A 2007; 104 (25) 10305-10309
    CrossrefPubMedGoogle Scholar
  • 21 Binder WH, Lomoschitz M, Sachsenhofer R, Friedbacher G. Reversible and irreversible binding of nanoparticles to polymeric surfaces. J Nanomater 2009; 2009: 14
    PubMedGoogle Scholar
  • 22 Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev 2016; 98: 3-18
    CrossrefPubMedGoogle Scholar
  • 23 Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci 2014; 5 (01) 2-13
    CrossrefPubMedGoogle Scholar
  • 24 Vallet-Regí M. Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering. Chemistry 2006; 12 (23) 5934-5943
    CrossrefPubMedGoogle Scholar
  • 25 Wu J, Ding T, Sun J. Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus. Neurotoxicology 2013; 34: 243-253
    CrossrefPubMedGoogle Scholar
  • 26 Yazdi AS, Guarda G, Riteau N. , et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci U S A 2010; 107 (45) 19449-19454
    CrossrefPubMedGoogle Scholar
  • 27 Murphy A, Casey A, Byrne G, Chambers G, Howe O. Silver nanoparticles induce pro-inflammatory gene expression and inflammasome activation in human monocytes. J Appl Toxicol 2016; 36 (10) 1311-1320
    CrossrefPubMedGoogle Scholar
  • 28 Park E-J, Lee G-H, Yoon C. , et al. Biodistribution and toxicity of spherical aluminum oxide nanoparticles. J Appl Toxicol 2016; 36 (03) 424-433
    CrossrefPubMedGoogle Scholar
  • 29 Liu Q, Babadjouni R, Radwanski R. , et al. Stroke damage is exacerbated by nano-size particulate matter in a Mouse model. PLoS One 2016; 11 (04) e0153376
    CrossrefPubMedGoogle Scholar
  • 30 Kane AB, Hurt RH, Gao H. The asbestos-carbon nanotube analogy: an update. Toxicol Appl Pharmacol 2018; 361: 68-80
    CrossrefPubMedGoogle Scholar
  • 31 Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A. Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl (Wien) 2010; 106: 359-364
    PubMedGoogle Scholar
  • 32 Haley MJ, Lawrence CB. The blood-brain barrier after stroke: structural studies and the role of transcytotic vesicles. J Cereb Blood Flow Metab 2017; 37 (02) 456-470
    PubMedGoogle Scholar
  • 33 Wei W, Zhang X, Chen X, Zhou M, Xu R, Zhang X. Smart surface coating of drug nanoparticles with cross-linkable polyethylene glycol for bio-responsive and highly efficient drug delivery. Nanoscale 2016; 8 (15) 8118-8125
    CrossrefPubMedGoogle Scholar
  • 34 Muir KW, Santosh C. Imaging of acute stroke and transient ischaemic attack. J Neurol Neurosurg Psychiatry 2005; 76 (Suppl. 03) iii19-iii28
    PubMedGoogle Scholar
  • 35 Agarwal S, Jones PS, Alawneh JA. , et al. Does perfusion computed tomography facilitate clinical decision making for thrombolysis in unselected acute patients with suspected ischaemic stroke?. Cerebrovasc Dis 2011; 32 (03) 227-233
    CrossrefPubMedGoogle Scholar
  • 36 Das NM, Hatsell S, Nannuru K. , et al. In vivo quantitative microcomputed tomographic analysis of vasculature and organs in a normal and diseased mouse model. PLoS One 2016; 11 (02) e0150085
    CrossrefPubMedGoogle Scholar
  • 37 Mishra NK, Albers GW, Davis SM. , et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010; 41 (01) e25-e33
    PubMedGoogle Scholar
  • 38 Toth GB, Varallyay CG, Horvath A. , et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 2017; 92 (01) 47-66
    CrossrefPubMedGoogle Scholar
  • 39 Qin J, Zhou S, Li Z, Chen Y, Qin Q, Ai T. Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction. Exp Ther Med 2018; 16 (04) 3303-3308
    PubMedGoogle Scholar
  • 40 Ewing JR, Knight RA, Nagaraja TN. , et al. Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med 2003; 50 (02) 283-292
    CrossrefPubMedGoogle Scholar
  • 41 Liu DF, Qian C, An YL, Chang D, Ju SH, Teng GJ. Magnetic resonance imaging of post-ischemic blood-brain barrier damage with PEGylated iron oxide nanoparticles. Nanoscale 2014; 6 (24) 15161-15167
    CrossrefPubMedGoogle Scholar
  • 42 Wei H, Bruns OT, Kaul MG. , et al. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents. Proc Natl Acad Sci U S A 2017; 114 (09) 2325-2330
    CrossrefPubMedGoogle Scholar
  • 43 Farr TD, Lai CH, Grünstein D. , et al. Imaging early endothelial inflammation following stroke by core shell silica superparamagnetic glyconanoparticles that target selectin. Nano Lett 2014; 14 (04) 2130-2134
    CrossrefPubMedGoogle Scholar
  • 44 Shah BN, Chahal NS, Kooner JS, Senior R. Contrast-enhanced ultrasonography vs B-mode ultrasound for visualization of intima-media thickness and detection of plaques in human carotid arteries. Echocardiography 2017; 34 (05) 723-730
    CrossrefPubMedGoogle Scholar
  • 45 Luke GP, Hannah AS, Emelianov SY. Super-resolution ultrasound imaging in vivo with transient laser-activated nanodroplets. Nano Lett 2016; 16 (04) 2556-2559
    CrossrefPubMedGoogle Scholar
  • 46 Ludewig P, Gdaniec N, Sedlacik J. , et al. Magnetic particle imaging for real-time perfusion imaging in acute stroke. ACS Nano 2017; 11 (10) 10480-10488
    CrossrefPubMedGoogle Scholar
  • 47 Brea D, Agulla J, Staes A. , et al. Study of protein expression in peri-infarct tissue after cerebral ischemia. Sci Rep 2015; 5: 12030
    CrossrefPubMedGoogle Scholar
  • 48 Hoyte LC, Brooks KJ, Nagel S. , et al. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab 2010; 30 (06) 1178-1187
    PubMedGoogle Scholar
  • 49 Blau R, Epshtein Y, Pisarevsky E. , et al. Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins. Theranostics 2018; 8 (13) 3437-3460
    CrossrefPubMedGoogle Scholar
  • 50 Joo J, Liu X, Kotamraju VR, Ruoslahti E, Nam Y, Sailor MJ. Gated luminescence imaging of silicon nanoparticles. ACS Nano 2015; 9 (06) 6233-6241
    CrossrefPubMedGoogle Scholar
  • 51 Kim T, Lemaster JE, Chen F, Li J, Jokerst JV. Photoacoustic imaging of human mesenchymal stem cells labeled with Prussian Blue-Poly(l-lysine) nanocomplexes. ACS Nano 2017; 11 (09) 9022-9032
    CrossrefPubMedGoogle Scholar
  • 52 Muir KW. Clinical trial design for stem cell therapies in stroke: what have we learned?. Neurochem Int 2017; 106: 108-113
    CrossrefPubMedGoogle Scholar
  • 53 Li J, Wu C, Hou P, Zhang M, Xu K. One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo. Biosens Bioelectron 2018; 102: 1-8
    CrossrefPubMedGoogle Scholar
  • 54 Lin KY, Kwong GA, Warren AD, Wood DK, Bhatia SN. Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 2013; 7 (10) 9001-9009
    CrossrefPubMedGoogle Scholar
  • 55 Sun Y, Gao W, Zhao Y. , et al. Visualization and inhibition of mitochondria-nuclear translocation of apoptosis inducing factor by a graphene oxide-DNA nanosensor. Anal Chem 2017; 89 (08) 4642-4647
    CrossrefPubMedGoogle Scholar
  • 56 Gong T, Hong ZY, Chen CH, Tsai CY, Liao LD, Kong KV. Optical interference-free surface-enhanced Raman scattering CO-nanotags for logical multiplex detection of vascular disease-related biomarkers. ACS Nano 2017; 11 (03) 3365-3375
    CrossrefPubMedGoogle Scholar
  • 57 Hu Y, Cheng H, Zhao X. , et al. Surface-enhanced Raman scattering active gold nanoparticles with enzyme-mimicking activities for measuring glucose and lactate in living tissues. ACS Nano 2017; 11 (06) 5558-5566
    CrossrefPubMedGoogle Scholar
  • 58 Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol 2012; 74 (02) 230-240
    CrossrefPubMedGoogle Scholar
  • 59 Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 2008; 39 (10) 2902-2909
    CrossrefPubMedGoogle Scholar
  • 60 Misra S, Kumar A, Kumar P. , et al. Blood-based protein biomarkers for stroke differentiation: a systematic review. Proteomics Clin Appl 2017; 11: 9-10
    PubMedGoogle Scholar
  • 61 Monbailliu T, Goossens J, Hachimi-Idrissi S. Blood protein biomarkers as diagnostic tool for ischemic stroke: a systematic review. Biomarkers Med 2017; 11 (06) 503-512
    CrossrefPubMedGoogle Scholar
  • 62 Simats A, García-Berrocoso T, Montaner J. Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochim Biophys Acta 2016; 1862 (03) 411-424
    PubMedGoogle Scholar
  • 63 Glushakova OY, Glushakov AV, Miller ER, Valadka AB, Hayes RL. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. Brain Circ 2016; 2 (01) 28-47
    CrossrefPubMedGoogle Scholar
  • 64 Ilies M, Iuga CA, Loghin F, Dhople VM, Hammer E. Plasma protein absolute quantification by nano-LC Q-TOF UDMSE for clinical biomarker verification. Clujul Med 2017; 90 (04) 425-430
    PubMedGoogle Scholar
  • 65 Chen JQ, Wakefield LM, Goldstein DJ. Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med 2015; 13: 182
    CrossrefPubMedGoogle Scholar
  • 66 Ahmad R, Mahmoudi T, Ahn MS, Hahn YB. Recent advances in nanowires-based field-effect transistors for biological sensor applications. Biosens Bioelectron 2018; 100: 312-325
    CrossrefPubMedGoogle Scholar
  • 67 Wang Z, Lee S, Koo K, Kim K. Nanowire-based sensors for biological and medical applications. IEEE Trans Nanobioscience 2016; 15 (03) 186-199
    CrossrefPubMedGoogle Scholar
  • 68 Lu N, Gao A, Dai P. , et al. Ultrasensitive detection of dual cancer biomarkers with integrated CMOS-compatible nanowire arrays. Anal Chem 2015; 87 (22) 11203-11208
    CrossrefPubMedGoogle Scholar
  • 69 Stern E, Vacic A, Rajan NK. , et al. Label-free biomarker detection from whole blood. Nat Nanotechnol 2010; 5 (02) 138-142
    CrossrefPubMedGoogle Scholar
  • 70 Biodirection. Tbit™ Blood Testing Platform. 2019 . Available at: http://biodirection.com/tbit-platform/ . Accessed March 13, 2019
    PubMed
  • 71 Ren C, Kobeissy F, Alawieh A. , et al. Assessment of serum UCH-L1 and GFAP in acute stroke patients. Sci Rep 2016; 6: 24588-24588
    CrossrefPubMedGoogle Scholar
  • 72 Hasanzadeh M, Rahimi S, Solhi E. , et al. Probing the antigen-antibody interaction towards ultrasensitive recognition of cancer biomarker in adenocarcinoma cell lysates using layer-by-layer assembled silver nano-cubics with porous structure on cysteamine caped GQDs. Microchem J 2018; 143: 379-392
    CrossrefPubMedGoogle Scholar
  • 73 Bravo K, Ortega FG, Messina GA, Sanz MI, Fernández-Baldo MA, Raba J. Integrated bio-affinity nano-platform into a microfluidic immunosensor based on monoclonal bispecific trifunctional antibodies for the electrochemical determination of epithelial cancer biomarker. Clin Chim Acta 2017; 464: 64-71
    CrossrefPubMedGoogle Scholar
  • 74 Zhou YC, Zhao M, Yu YQ. , et al. Three-dimensional nano-network composed of Pt nanoparticles functionalized Mn-doped CeO2 and hemin/G-quadruplex as electrocatalysts for cardiovascular biomarker detection. Sens Actuators B Chem 2017; 246: 1-8
    CrossrefPubMedGoogle Scholar
  • 75 Quero G, Consales M, Severino R. , et al. Long period fiber grating nano-optrode for cancer biomarker detection. Biosens Bioelectron 2016; 80: 590-600
    CrossrefPubMedGoogle Scholar
  • 76 Niu G, Chen X. The role of molecular imaging in drug delivery. Drug Deliv (Lond) 2009; 3: 109-113
    PubMedGoogle Scholar
  • 77 Kim J-Y, Ryu JH, Schellingerhout D. , et al. Direct imaging of cerebral thromboemboli using computed tomography and fibrin-targeted gold nanoparticles. Theranostics 2015; 5 (10) 1098-1114
    CrossrefPubMedGoogle Scholar
  • 78 Voros E, Cho M, Ramirez M. , et al. TPA immobilization on iron oxide nanocubes and localized magnetic hyperthermia accelerate blood clot lysis. Adv Funct Mater 2015; 25 (11) 1709-1718
    CrossrefPubMedGoogle Scholar
  • 79 Li M, Liu Y, Chen J. , et al. Platelet bio-nanobubbles as microvascular recanalization nanoformulation for acute ischemic stroke lesion theranostics. Theranostics 2018; 8 (18) 4870-4883
    CrossrefPubMedGoogle Scholar
  • 80 Agulla J, Brea D, Campos F. , et al. In vivo theranostics at the peri-infarct region in cerebral ischemia. Theranostics 2013; 4 (01) 90-105
    PubMedGoogle Scholar
  • 81 Campbell BCV, Donnan GA, Mitchell PJ, Davis SM. Endovascular thrombectomy for stroke: current best practice and future goals. Stroke Vasc Neurol 2016; 1 (01) 16-22
    CrossrefPubMedGoogle Scholar
  • 82 Thiebaut AM, Gauberti M, Ali C. , et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol 2018; 17 (12) 1121-1132
    CrossrefPubMedGoogle Scholar
  • 83 Weitz JI, Leslie B, Hirsh J, Klement P. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest 1993; 91 (04) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 84 Niego B, Medcalf RL. Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?. J Cereb Blood Flow Metab 2014; 34 (08) 1283-1296
    Google Scholar
  • 85 Caplan LR. Stroke thrombolysis: slow progress. Circulation 2006; 114 (03) 187-190
    CrossrefPubMedGoogle Scholar
  • 86 Liu S, Feng X, Jin R, Li G. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. Expert Opin Drug Deliv 2018; 15 (02) 173-184
    CrossrefPubMedGoogle Scholar
  • 87 Zamanlu M, Farhoudi M, Eskandani M. , et al. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. J Drug Target 2018; 26 (02) 95-109
    CrossrefPubMedGoogle Scholar
  • 88 Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009; 30 (29) 5751-5756
    CrossrefPubMedGoogle Scholar
  • 89 Uesugi Y, Kawata H, Saito Y, Tabata Y. Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator. J Drug Target 2012; 20 (03) 224-234
    CrossrefPubMedGoogle Scholar
  • 90 Colasuonno M, Palange AL, Aid R. , et al. Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots. ACS Nano 2018; 12 (12) 12224-12237
    CrossrefPubMedGoogle Scholar
  • 91 Absar S, Choi S, Yang VC, Kwon YM. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis. J Control Release 2012; 157 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 92 Chung TW, Wang SS, Tsai WJ. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. Biomaterials 2008; 29 (02) 228-237
    CrossrefPubMedGoogle Scholar
  • 93 Mahmoodi M, Khosroshahi ME, Atyabi F. Dynamic study of PLGA/CS nanoparticles delivery containing drug model into phantom tissue using CO2 laser for clinical applications. J Biophotonics 2011; 4 (06) 403-414
    CrossrefPubMedGoogle Scholar
  • 94 Wen AM, Wang Y, Jiang K. , et al. Shaping bio-inspired nanotechnologies to target thrombosis for dual optical-magnetic resonance imaging. J Mater Chem B Mater Biol Med 2015; 3 (29) 6037-6045
    CrossrefPubMedGoogle Scholar
  • 95 Pitek AS, Park J, Wang Y. , et al. Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage. Nanoscale 2018; 10 (35) 16547-16555
    CrossrefPubMedGoogle Scholar
  • 96 Huang Y, Yu L, Ren J. , et al. An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy. J Control Release 2019; 300: 1-12
    CrossrefPubMedGoogle Scholar
  • 97 Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011; 7 (07) 400-409
    CrossrefPubMedGoogle Scholar
  • 98 Francis CW. Ultrasound-enhanced thrombolysis. Echocardiography 2001; 18 (03) 239-246
    CrossrefPubMedGoogle Scholar
  • 99 Alexandrov AV, Mikulik R, Ribo M. , et al. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke 2008; 39 (05) 1464-1469
    CrossrefPubMedGoogle Scholar
  • 100 Schellinger PD, Alexandrov AV, Barreto AD. , et al; CLOTBUSTER Investigators. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial. Int J Stroke 2015; 10 (07) 1141-1148
    CrossrefPubMedGoogle Scholar
  • 101 de Saint Victor M, Crake C, Coussios CC, Stride E. Properties, characteristics and applications of microbubbles for sonothrombolysis. Expert Opin Drug Deliv 2014; 11 (02) 187-209
    CrossrefPubMedGoogle Scholar
  • 102 Laing ST, Moody MR, Kim H. , et al. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thromb Res 2012; 130 (04) 629-635
    CrossrefPubMedGoogle Scholar
  • 103 Hua X, Zhou L, Liu P. , et al. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. J Thromb Thrombolysis 2014; 38 (01) 57-64
    CrossrefPubMedGoogle Scholar
  • 104 Alexandrov AV, Molina CA, Grotta JC. , et al; CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351 (21) 2170-2178
    CrossrefPubMedGoogle Scholar
  • 105 Molina CA, Barreto AD, Tsivgoulis G. , et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009; 66 (01) 28-38
    CrossrefPubMedGoogle Scholar
  • 106 Nacu A, Kvistad CE, Naess H. , et al. NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): randomized controlled contrast-enhanced sonothrombolysis in an unselected acute ischemic stroke population. Stroke 2017; 48 (02) 335-341
    CrossrefPubMedGoogle Scholar
  • 107 Teng Y, Jin H, Nan D. , et al. In vivo evaluation of urokinase-loaded hollow nanogels for sonothrombolysis on suture embolization-induced acute ischemic stroke rat model. Bioact Mater 2017; 3 (01) 102-109
    PubMedGoogle Scholar
  • 108 Heid S, Unterweger H, Tietze R. , et al. Synthesis and characterization of tissue plasminogen activator-functionalized superparamagnetic iron oxide nanoparticles for targeted fibrin clot dissolution. Int J Mol Sci 2017; 18 (09) E1837
    CrossrefPubMedGoogle Scholar
  • 109 Bi F, Zhang J, Su Y, Tang YC, Liu JN. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials 2009; 30 (28) 5125-5130
    CrossrefPubMedGoogle Scholar
  • 110 Chen J-P, Yang P-C, Ma Y-H, Wu T. Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator. Carbonate Polym 2011; 84 (01) 364-372
    PubMedGoogle Scholar
  • 111 Yang H-W, Hua M-Y, Lin K-J. , et al. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. Int J Nanomedicine 2012; 7: 5159-5173
    PubMedGoogle Scholar
  • 112 Chen JP, Yang PC, Ma YH, Tu SJ, Lu YJ. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Int J Nanomedicine 2012; 7: 5137-5149
    PubMedGoogle Scholar
  • 113 Cheng R, Huang W, Huang L. , et al. Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors. ACS Nano 2014; 8 (08) 7746-7754
    CrossrefPubMedGoogle Scholar
  • 114 Kempe M, Kempe H, Snowball I. , et al. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials 2010; 31 (36) 9499-9510
    CrossrefPubMedGoogle Scholar
  • 115 Bonnard T, Tennant Z, Niego B. , et al. Novel thrombolytic drug based on thrombin cleavable microplasminogen coupled to a single-chain antibody specific for activated GPIIb/IIIa. J Am Heart Assoc 2017; 6 (02) e004535
    PubMedGoogle Scholar
  • 116 Zhang N, Li C, Zhou D. , et al. Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomater 2018; 70: 227-236
    CrossrefPubMedGoogle Scholar
  • 117 Arjmand S, Pardakhty A, Forootanfar H, Khazaeli P. A road to bring Brij52 back to attention: shear stress sensitive Brij52 niosomal carriers for targeted drug delivery to obstructed blood vessels. Med Hypotheses 2018; 121: 137-141
    CrossrefPubMedGoogle Scholar
  • 118 Molloy CP, Yao Y, Kammoun H. , et al. Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation. J Thromb Haemost 2017; 15 (05) 972-982
    CrossrefPubMedGoogle Scholar
  • 119 Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview. Circ Res 2017; 120 (03) 541-558
    CrossrefPubMedGoogle Scholar
  • 120 O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59 (03) 467-477
    CrossrefPubMedGoogle Scholar
  • 121 Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64 (07) 686-700
    CrossrefPubMedGoogle Scholar
  • 122 Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004; 56 (04) 468-477
    CrossrefPubMedGoogle Scholar
  • 123 Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release 2018; 270: 290-303
    CrossrefPubMedGoogle Scholar
  • 124 Koffie RM, Farrar CT, Saidi L-J, William CM, Hyman BT, Spires-Jones TL. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A 2011; 108 (46) 18837-18842
    CrossrefPubMedGoogle Scholar
  • 125 Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine (Lond) 2009; 5 (04) 369-377
    CrossrefPubMedGoogle Scholar
  • 126 Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J Drug Deliv 2011; 2011: 469679
    PubMedGoogle Scholar
  • 127 Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017; 264: 306-332
    CrossrefPubMedGoogle Scholar
  • 128 Cheng Y, Dai Q, Morshed RA. , et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small 2014; 10 (24) 5137-5150
    PubMedGoogle Scholar
  • 129 Trickler WJ, Lantz SM, Murdock RC. , et al. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol Sci 2010; 118 (01) 160-170
    CrossrefPubMedGoogle Scholar
  • 130 Grabrucker AM, Rowan M, Garner CC. Brain-delivery of zinc-ions as potential treatment for neurological diseases: mini review. Drug Deliv Lett 2011; 1 (01) 13-23
    PubMedGoogle Scholar
  • 131 Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release 2016; 240: 332-348
    CrossrefPubMedGoogle Scholar
  • 132 Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano Today 2015; 10 (04) 487-510
    CrossrefPubMedGoogle Scholar
  • 133 Harris NM, Ritzel R, Mancini NS. , et al. Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery. Pharmacol Biochem Behav 2016; (150-151): 48-56
    PubMedGoogle Scholar
  • 134 Gaudin A, Yemisci M, Eroglu H. , et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 2014; 9 (12) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 135 Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012; 119 (20) 4752-4761
    CrossrefPubMedGoogle Scholar
  • 136 Fukuta T, Asai T, Yanagida Y. , et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J 2017; 31 (05) 1879-1890
    CrossrefPubMedGoogle Scholar
  • 137 Fukuta T, Yanagida Y, Asai T, Oku N. Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis. Biochem Biophys Res Commun 2018; 495 (01) 873-877
    CrossrefPubMedGoogle Scholar
  • 138 Guo X, Deng G, Liu J. , et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy. ACS Nano 2018; 12 (08) 8723-8732
    CrossrefPubMedGoogle Scholar
  • 139 Wang T, Hou Y, Bu B. , et al. Timely visualization of the collaterals formed during acute ischemic stroke with Fe3O4 nanoparticle-based MR imaging probe. Small 2018; 14 (23) e1800573
    CrossrefPubMedGoogle Scholar
  • 140 Hoehn B, Ringer TM, Xu L. , et al. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 2001; 21 (11) 1303-1309
    PubMedGoogle Scholar
  • 141 Weinstein PR, Hong S, Sharp FR. Molecular identification of the ischemic penumbra. Stroke 2004; 35 (11) (Suppl. 01) 2666-2670
    CrossrefPubMedGoogle Scholar
  • 142 Bitner BR, Marcano DC, Berlin JM. , et al. Antioxidant carbon particles improve cerebrovascular dysfunction following traumatic brain injury. ACS Nano 2012; 6 (09) 8007-8014
    CrossrefPubMedGoogle Scholar
  • 143 Berlin JM, Leonard AD, Pham TT. , et al. Effective drug delivery, in vitro and in vivo, by carbon-based nanovectors noncovalently loaded with unmodified Paclitaxel. ACS Nano 2010; 4 (08) 4621-4636
    CrossrefPubMedGoogle Scholar
  • 144 Fabian RH, Derry PJ, Rea HC. , et al. Efficacy of novel carbon nanoparticle antioxidant therapy in a severe model of reversible middle cerebral artery stroke in acutely hyperglycemic rats. Front Neurol 2018; 9: 199
    CrossrefPubMedGoogle Scholar
  • 145 Shen Y, Cao B, Snyder NR, Woeppel KM, Eles JR, Cui XT. ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood-brain barrier. J Nanobiotechnology 2018; 16 (01) 13
    CrossrefPubMedGoogle Scholar
  • 146 Lv W, Xu J, Wang X, Li X, Xu Q, Xin H. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment. ACS Nano 2018; 12 (06) 5417-5426
    CrossrefPubMedGoogle Scholar
  • 147 Shen Z, Liu T, Li Y. , et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano 2018; 12 (11) 11355-11365
    CrossrefPubMedGoogle Scholar
  • 148 Petro M, Jaffer H, Yang J, Kabu S, Morris VB, Labhasetwar V. Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. Biomaterials 2016; 81: 169-180
    CrossrefPubMedGoogle Scholar
  • 149 Yun S, Shin TH, Lee JH. , et al. Design of magnetically labeled cells (Mag-Cells) for in vivo control of stem cell migration and differentiation. Nano Lett 2018; 18 (02) 838-845
    CrossrefPubMedGoogle Scholar
  • 150 Chung CY, Lin MH, Lee IN, Lee TH, Lee MH, Yang JT. Brain-derived neurotrophic factor loaded PS80 PBCA nanocarrier for in vitro neural differentiation of mouse induced pluripotent stem cells. Int J Mol Sci 2017; 18 (03) E663
    CrossrefPubMedGoogle Scholar
  • 151 Pluta RM, Hansen-Schwartz J, Dreier J. , et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res 2009; 31 (02) 151-158
    CrossrefPubMedGoogle Scholar
  • 152 Hwang PK, Greer J. Interaction between hemoglobin subunits in the hemoglobin. haptoglobin complex. J Biol Chem 1980; 255 (07) 3038-3041
    CrossrefPubMedGoogle Scholar
  • 153 Kristiansen M, Graversen JH, Jacobsen C. , et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409 (6817): 198-201
    CrossrefPubMedGoogle Scholar
  • 154 Liu R, Cao S, Hua Y, Keep RF, Huang Y, Xi G. CD163 expression in neurons after experimental intracerebral hemorrhage. Stroke 2017; 48 (05) 1369-1375
    CrossrefPubMedGoogle Scholar
  • 155 Galea J, Cruickshank G, Teeling JL. , et al. The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage. J Neurochem 2012; 121 (05) 785-792
    CrossrefPubMedGoogle Scholar
  • 156 Betzer O, Perets N, Angel A. , et al. In vivo neuroimaging of exosomes using gold nanoparticles. ACS Nano 2017; 11 (11) 10883-10893
    CrossrefPubMedGoogle Scholar
  • 157 Li H, Ohta H, Tahara Y. , et al. Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model. Sci Rep 2015; 5: 15271
    CrossrefPubMedGoogle Scholar
  • 158 Kazemi Korayem A, Ghamami S, Bahrami Z. Fractal properties and morphological investigation of nano hydrochlorothiazide is used to treat hypertension. BMC Pharmacol Toxicol 2018; 19 (01) 70
    CrossrefPubMedGoogle Scholar
  • 159 Khan A, Aqil M, Imam SS. , et al. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: characterization, nasal absorption, histopathology and cell line study. Int J Biol Macromol 2018; 116: 1260-1267
    CrossrefPubMedGoogle Scholar
  • 160 Jiang Y, Wang X, Liu X. , et al. Enhanced antiglioma efficacy of ultrahigh loading capacity paclitaxel prodrug conjugate self-assembled targeted nanoparticles. ACS Appl Mater Interfaces 2017; 9 (01) 211-217
    CrossrefPubMedGoogle Scholar
  • 161 Hall CN, Reynell C, Gesslein B. , et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014; 508 (7494): 55-60
    CrossrefPubMedGoogle Scholar
  • 162 Guan S, Zhao Y, Lu J. , et al. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis. Oncotarget 2016; 7 (46) 75914-75925
    CrossrefPubMedGoogle Scholar
  • 163 Loi M, Marchiò S, Becherini P. , et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010; 145 (01) 66-73
    CrossrefPubMedGoogle Scholar
  • 164 Kang E, Shin JW. Pericyte-targeting drug delivery and tissue engineering. Int J Nanomedicine 2016; 11: 2397-2406
    PubMedGoogle Scholar